The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study
EntityUAM. Departamento de Medicina
10.3390/curroncol29040179Current Oncology 29.4 (2022): 2199–2210
Funded byThis research received no external funding
Subjectsbreast cancer; endocrine therapy; neoadjuvant; resistance; Medicina
Rights© 2022 by the authors
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Purpose: Neoadjuvant endocrine treatment (NET) has become a useful tool for the down-staging of luminal-like breast cancers in postmenopausal patients. It enables us to increase breast-conserving surgery (BCS) rates, provides an opportunity for us to assess in vivo NET effectiveness, and allows us to study any biological changes that may act as valid biomarkers. The purpose of this study was to evaluate the safety and effectiveness of NET, and to assess the role of Ki67 proliferation rate changes as an indicator of endocrine responsiveness. Methods: From 2016 to 2020, a single-institution cohort of patients, treated with NET and further surgery, was evaluated. In patients with Ki67 ≥ 10%, a second core biopsy was performed after four weeks. Information regarding histopathological and clinical changes was gathered. Results: A total of 115 estrogen receptor-positive (ER+)/HER2-negative patients were included. The median treatment duration was 5.0 months (IQR: 2.0–6.0). The median maximum size in the surgical sample was 40% smaller than the pretreatment size measured by ultrasound (p < 0.0001). The median pretreatment Ki67 expression was 20.0% (IQR: 12.0–30.0), and was reduced to 5.0% (IQR: 1.8–10.0) after four weeks, and to 2.0% (IQR: 1.0–8.0) in the surgical sample (p < 0.0001). BCS was performed on 98 patients (85.2%). No pathological complete responses were recorded. A larger Ki67 fold change after four weeks was significantly related to a PEPI score of zero (p < 0.002). No differences were observed between luminal A-and B-like tumors, with regard to fold change and PEPI score. Conclusions: In our cohort, NET was proven to be effective for tumor size and Ki67 downstaging. This resulted in a higher rate of conservative surgery, aided in therapeutic decision making, provided prognostic information, and constituted a safe and well-tolerated approach
Files in this item
Google Scholar:Martí, Covadonga - Yébenes, Laura - Oliver, José María - Moreno, Elisa - Frías, Laura - Berjón, Alberto - Loayza, Adolfo - Meléndez, Marcos - Roca, María José - Córdoba, Vicenta - Hardisson Hernáez, David Alonso - Rodríguez, María Ángeles - Sánchez Méndez, José Ignacio
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma
Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma